EQL Pharma publishes 2025/2026 annual report

• EQL Pharma published its 2025/2026 annual report, flagging weaker growth and profitability tied to delayed launches and supply-chain disruption.
• Management expanded headcount, upgraded key leadership roles, added a Specialty Generics business area, started building positions in Germany and the Netherlands.
• Mellozzan gained traction in new markets, including a UK launch; Turkey launch planned for 2026; Italy launch targeted in 2027/28.
• Memprex expanded in Europe, including a June 2026 launch in Germany under Cystohipp; France launch in June 2026 under Altaromin.
• Outlook calls for roughly 15% growth in 2026/27, with focus on restoring launch pace, tightening supplier coordination, lowering costs, containing fixed expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.